Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab safety study in recurrent or metastatic platinum-refractory SCCHN
2017-000424-10Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Unicancer. Primary endpoint: Incidence of high-grade adverse events of interest. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-000424-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000424-10.